PP60 SRC &THE POLYOMA MT PROTEIN INTERACTION

Information

  • Research Project
  • 3482099
  • ApplicationId
    3482099
  • Core Project Number
    R37CA027951
  • Full Project Number
    7R37CA027951-13
  • Serial Number
    27951
  • FOA Number
  • Sub Project Id
  • Project Start Date
    5/1/1980 - 45 years ago
  • Project End Date
    6/30/1993 - 31 years ago
  • Program Officer Name
  • Budget Start Date
    9/30/1992 - 32 years ago
  • Budget End Date
    6/30/1993 - 31 years ago
  • Fiscal Year
    1992
  • Support Year
    13
  • Suffix
  • Award Notice Date
    9/22/1992 - 32 years ago

PP60 SRC &THE POLYOMA MT PROTEIN INTERACTION

The cellular src gene product has served as a model protein for studies on the regulation of the functional activity of a tyrosine protein kinase and for investigations of the mechanism of oncogenic activation of this class of proto-oncogene products. One project in this proposal is designed to further delineate, and characterize, the regions within the amino-terminal half of the c- src protein that quantitatively and qualitatively regulate its functional activity. The analysis of mutant forms of the c-src gene product that contain mutations within the amino-terminal half of pp60c-src suggest at least two distinct regulatory regions in this half of the molecule: alterations in one region cause a partial activation of transforming activity and an enhancement in intracellular tyrosine phosphorylation; alterations in a second region cause dramatic changes in the phenotype of transforming variants of pp60c-src, possibly by altering substrate selection in vivo. We will construct a series of new mutants to further characterize the borders of these regulatory regions and the nature of the regulation mediated within this domain of pp60c- src. We will also examine phosphorylation of tyrosine 527, which has been proposed to have a negative effect of the tyrosine kinase activity and the oncogenicity of pp60c-src. The experiments described in this proposal will examine the conditions that affect phosphorylation of tyrosine 527, and examine whether this event is mediated by autophosphorylation, or by another tyrosine kinase. These studies will involve mutational alterations which change the localization of pp60c-src and which prevent intramolecular autophosphorylation. In addition, we will analyse the expression of pp60c-src in yeast, where phosphorylation by endogenous tryosine kinases does not take place, and will examine the conditions that affect the phosphorylation of pp60c-src on tyrosine 527 in vitro in animal cells to identify another putative tryosine 527 kinase, or to determine the conditions that are necessary for autophosphorylation at this site). Finally, we will continue to investigate the interaction of pp60c- src with the polyoma virus middle T antigen in order to determine the regions of pp60c-src that are necessary for the interaction with middle T antigen and for activation of pp60c-src middle T antigen. This will serve as a model system for studying how protein-protein interactions can regulate the activity of pp60c- src.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R37
  • Administering IC
    CA
  • Application Type
    7
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    VR
  • Study Section Name
    Virology Study Section
  • Organization Name
    ARIAD PHARMACEUTICALS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    CAMBRIDGE
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    02139
  • Organization District
    UNITED STATES